Insight Molecular Diagnostics Inc. (IMDX)vsNatera Inc (NTRA)
IMDX
Insight Molecular Diagnostics Inc.
$5.24
-20.00%
HEALTHCARE · Cap: $169.20M
NTRA
Natera Inc
$215.31
-3.06%
HEALTHCARE · Cap: $30.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 128218% more annual revenue ($2.50B vs $1.95M). IMDX leads profitability with a 0.0% profit margin vs -9.1%. NTRA earns a higher WallStSmart Score of 31/100 (F).
IMDX
Avoid17
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 17.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IMDX
The strongest argument for IMDX centers on Debt/Equity.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : IMDX
The primary concerns for IMDX are EPS Growth, Market Cap, Profit Margin.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
IMDX profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.
IMDX carries more volatility with a beta of 1.63 — expect wider price swings.
NTRA is growing revenue faster at 38.8% — sustainability is the question.
NTRA generates stronger free cash flow (18M), providing more financial flexibility.
Bottom Line
NTRA scores higher overall (31/100 vs 17/100) and 38.8% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insight Molecular Diagnostics Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?